The Trade Alliance to Promote Prosperity recently joined 10 coalition partners in signing a letter urging President Trump to reject Korea’s discriminatory digital trade practices.
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., contributed comments for a video from a coalition of conservative and free market organizations, urging Congress to oppose Most Favored Nation drug pricing schemes.
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., penned an op-ed for the DC Journal/Inside Sources today, “On Drugs, Is Trump Tired of Winning or What?” In the op-ed, TAPP explains why President Trump’s Most-Favored-Nation drug pricing scheme would be bad for American pharmaceutical innovation and for patients.
Read MoreOn Thursday, July 24, the Justice Department’s Antitrust Division and the Federal Trade Commission, along with the Department of Commerce and the Department of Health and Human Services, hosted their second of three listening sessions as part of implementing President Trump’s Executive Order No. 14273, Lowering Drug Prices by Once Again Putting Americans First.
Read MoreThe Trade Alliance to Promote Prosperity is applauding the efforts of 18 Republican Senators who sent a letter to U.S. Commerce Secretary Howard Lutnick and U.S. Trade Representative Jamieson Greer endorsing efforts “to ensure foreign nations pay their fair share toward the cost of pharmaceutical research and development.”
Read MoreCongresswoman Doris Matsui (D-CA) and Senator Peter Welch (D-VT) recently re-introduced a highly problematic bill called the 340B PATIENTS Act. The Trade Alliance to Promote Prosperity is encouraging Congress to reject the bill.
Read MoreThe Trade Alliance to Promote Prosperity recently signed onto a letter with 40+ coalition partners asking Congress to crack down on the 340B drug-pricing program, which provides discounted prices for certain so-called safety-net providers to purchase outpatient drugs.
Read MoreThe Trade Alliance to Promote Prosperity recently responded to the U.S. Trade Representative’s “Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation,” which the USTR issued pursuant Executive Order 14297, titled Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients. TAPP took the opportunity to highlight the detrimental effects of implementing an MFN scheme…
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., has an op-ed, "Trump Policy Threatens Biomedical Innovation," appearing in the DC Journal/Inside Sources today…
Read MoreOn April 15, the Secretary of Commerce initiated an investigation to determine the effects on the national security of imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients, and key starting materials, and derivative products of those items. The Trade Alliance to Promote Prosperity submitted comments in response to the agency’s request…
Read MoreThe Trade Alliance to Promote Prosperity is calling on the Trump Administration to restore recently cancelled research funding that the Department of Health and Human Services (HHS) had committed to developing a bird flu (H5N1) vaccine for humans…
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., appeared on the nationally syndicated Alan Nathan show with guest host John Hayward from Breitbart News on May 14 to discuss President Trump's tariffs…
Read MoreThe Trade Alliance to Promote Prosperity and 23 Partner Organizations today delivered a letter to U.S. House Speaker Mike Johnson and U.S. Senate Majority Leader John Thune to express strong opposition to the potential inclusion of a "Most Favored Nation" (MFN) drug pricing model in the forthcoming budget reconciliation package…
Read MoreThe new U.S.-U.K trade deal offers a few good elements for the United States, but major problems remain, especially affecting innovative American big-tech companies like Amazon, Google, and Meta.
Read MoreThe Trade Alliance to Promote Prosperity (TAPP) today sent a letter, along with an issue guide, to members of the U.S. House Energy & Commerce Committee, urging them to oppose a "Most Favored Nation" (MFN) drug pricing model, even as President Trump is actively pushing them to impose an MFC model on prescription drugs covered by Medicaid.
Read MoreThe Trade Alliance to Promote Prosperity signed onto a coalition letter, initiated by the Center for a Free Economy, opposing limits on the ability of businesses to deduct state and local taxes paid, unless offset dollar for dollar by new, broad-based, and permanent pro-growth tax reforms…
Read MoreTomorrow is World Intellectual Property (IP) Day 2024—the annual celebration of intellectual property rights. TAPP recognizes the importance of American IP as it bolsters domestic innovation and is crucial to our global competitive standing.
Read MoreThe Trade Alliance to Promote Prosperity applauds a newly released report from the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee which highlights the need for 340B program reform.
Read MoreThe Trade Alliance to Promote Prosperity applauds President Trump’s Executive Order, issued on April 15, 2025, “Lowering Drug Prices by Once Again Putting Americans First,” for its call on Congress to eliminate the “pill penalty.”
Read MoreThe imposition of wide-ranging and heavy-handed tariffs that run contrary to Trade Alliance to Promote Prosperity (TAPP) principles notwithstanding, President Trump deserves credit for at least expressing the intention to provide exemptions to U.S. companies so they can compete internationally. This intent is consistent with sentiments expressed by the overwhelming majority of 1,000 American voters recently surveyed by Fabrizio Lee & Associates (the president’s own pollster) on behalf of TAPP…
Read More